Wire · opportunities
Acepodia secures FDA clearance to begin Phase I ACE723 trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 September 2026 · Fusion42 review
Acepodia has received FDA clearance for its investigational new drug ACE723, enabling the start of a Phase I clinical trial targeting unresectable or metastatic hepatocellular carcinoma. The trial aims to assess safety, pharmacokinetics, and preliminary anti-tumour activity of ACE723, developed using Acepodia's dual-drug antibody conjugation platform.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 4 Sep 2026 and 7 Sep 2026.
◆ ◆ The Wire takeaway
You have an open door to the US cancer treatment market as ACE723 moves into human trials, presenting a chance to watch or partner on this dual-drug antibody technique with potential to tackle resistant tumours. Early-stage oncology biotech leaders should act now to align before dose results define the competitive landscape.
◆ Coverage
2 sources · first reported 4 Sep 2026 · latest 7 Sep 2026
◆ Related on Wire
◆ Topics